irbmThe DMPK team uses state of the art tools to support the selection of compounds with appropriate absorption, distribution, metabolism, and excretion properties for further development as drug candidates. With a state of the art mass spectrometric equipment – LC-MS/MS including Sciex API 4000 & API 5000, TSQ-AM, UPLC-QTOF, IRBM is your one-stop-shop for extensive range of in vitro and in vivo studies in preclinical species and in vitro studies in human preparations are available to fully profile compound candidates. Major attention is given to eliminate from further development compounds that are potentially toxic.

We profile and address specific DMPK issues:

High clearance, poor oral bioavailability

  • Specialized metabolic screens; transporter assays
  • Solubility; cell permeability

Availability in target organ (eg CNS)

  • Transporter assays

Drug-drug interaction potential

  • CYP inhibition and induction
  • Reaction phenotyping

Metabolic activation

  • In vitro trapping, covalent binding

Peptide PK

  • Drug quantification by bioassay, immunoassay

PK-PD Modeling

  • Human PK Prediction
  • In vitro-in vivo correlations, allometric scaling


Available DMPK studies

PK in all preclinical species
Automated blood sampling
Specialized in peptide and protein PK
Mechanistic PK Studies
Oral absorption and first pass extraction
Involvement of drug transporters in clearance and absorption mechanisms
Mass balance
Automated metabolic stability screening
Cytochrome P450 Induction and inhibition
Cell permeability and transport
Metabolic reaction phenotyping
Metabolite identification
Plasma protein binding, blood/plasma partition
Formulation support
Prediction of human PK

Comments are closed.